P1‐003: Apathy in Dementia Methylphenidate Trial (ADMET): Preliminary efficacy report
Bibliographic record
Abstract
Apathy is a distinct syndrome affecting Alzheimer's disease (AD) patients. Fifty percent of patients suffering from AD will present with apathy. The etiology of apathy in AD is unknown. Confluent information points to a potential association between dopaminergic disruption and apathy in AD. Preliminary data suggests that methylphenidate, a dopamine stimulant, may be effective on apathy in AD. The goal of ADMET was to explore the efficacy and safety of Methylphenidate in the treatment of apathy in AD. ADMET was a multi-site, 6 week, randomized placebo-controlled trial of the efficacy and safety of methylphenidate in mild-to-moderate AD. Patients with a major depressive episode (DSM-IV TR criteria) or psychotic symptoms were excluded. Cognition was assessed using the MMSE. Apathy and other behaviours were assessed using the Apathy Evaluation Scale (AES) and the Neuropsychiatric Inventory (NPI). Efficacy was assessed as the change in score of the AES and the Alzheimer's disease Cooperative Study - Clinical Global Impression of Change (CGIC) scale from baseline to 6 weeks. Secondary efficacy was assessed as the change in Digit Span from baseline to 6 weeks. In total, 60 patients were recruited (62% female, 92% Caucasian, mean (SD) age 76 ± 8 years, mean MMSE 20 ± 5). Subject retention was excellent. Only three participants dropped before week 6. Two of three did not return after baseline and one did not return after the week 2 visit. Recruited participants showed apathy on both the AES (51 ± 12), and NPI Apathy subscale (7.5 ± 2.3). Concomitant medications included cholinesterase inhibitors (72%), memantine (62%) and SSRIs (19%) and 13% of participants had a history of mood disorders. Preliminary results of the primary and secondary measures will be unveiled during this presentation. The treatment of apathy is a major clinical challenge for those treating AD. The results of this study will provide relevant information to clinicians managing this difficult group of patients.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.007 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".